Inspired by these findings, and in order to better control the quality of cell products and reduce production costs, we constructed bispecific BC19 CAR T cells targeting BCMA and CD19 and preliminarily verified their safety and efficacy in R/R MM patients. The gene discussed is CD19; the disease is Miyoshi myopathy.